Published in Cancer Res on July 01, 2008
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell (2010) 2.38
Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis (2009) 2.00
A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell (2011) 1.86
Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta (2010) 1.42
An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol Cancer Ther (2009) 1.36
Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. EMBO Rep (2012) 1.30
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A (2011) 1.24
ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol (2010) 1.04
Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol (2011) 1.04
Molecular insights into NF2/Merlin tumor suppressor function. FEBS Lett (2014) 1.03
Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways. Neoplasia (2011) 1.02
PAK kinase regulates Rac GTPase and is a potential target in human schwannomas. Exp Neurol (2009) 1.00
p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. PLoS One (2010) 0.97
NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation. Oncogene (2010) 0.97
MicroRNA-21 overexpression contributes to vestibular schwannoma cell proliferation and survival. Otol Neurotol (2010) 0.97
Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. Br J Pharmacol (2010) 0.96
Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. Laryngoscope (2011) 0.91
Merlin controls the repair capacity of Schwann cells after injury by regulating Hippo/YAP activity. J Cell Biol (2017) 0.90
Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro Oncol (2011) 0.89
NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations. Oncotarget (2014) 0.89
Plastic fantastic: Schwann cells and repair of the peripheral nervous system. Stem Cells Transl Med (2013) 0.87
Contribution of persistent C-Jun N-terminal kinase activity to the survival of human vestibular schwannoma cells by suppression of accumulation of mitochondrial superoxides. Neuro Oncol (2011) 0.87
Neurofibromatosis-related tumors: emerging biology and therapies. Curr Opin Pediatr (2015) 0.85
Role of Merlin/NF2 inactivation in tumor biology. Oncogene (2015) 0.85
Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/MET signaling pathway and androgen receptor deregulation. Int J Oncol (2013) 0.84
Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2. Clin Cancer Res (2013) 0.84
Artesunate induces necrotic cell death in schwannoma cells. Cell Death Dis (2014) 0.83
p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB. Glia (2014) 0.83
Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling. Onco Targets Ther (2008) 0.82
Merlin: the wizard requires protein stability to function as a tumor suppressor. Biochim Biophys Acta (2012) 0.82
The NFTI-QOL: A Disease-Specific Quality of Life Questionnaire for Neurofibromatosis 2. J Neurol Surg B Skull Base (2012) 0.82
Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumor suppressor merlin. Neoplasia (2011) 0.81
Treatment of vestibular schwannoma cells with ErbB inhibitors. Otol Neurotol (2012) 0.81
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am J Med Genet A (2014) 0.81
Merlin's tumor suppression linked to inhibition of the E3 ubiquitin ligase CRL4 (DCAF1). Cell Cycle (2010) 0.81
Molecular Mechanisms Involved in Schwann Cell Plasticity. Front Mol Neurosci (2017) 0.80
Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells. Brain (2013) 0.79
Estrogen receptor expression in sporadic vestibular schwannomas. Otol Neurotol (2011) 0.79
Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells. PLoS One (2012) 0.77
Gastric cancer-derived MSC-secreted PDGF-DD promotes gastric cancer progression. J Cancer Res Clin Oncol (2014) 0.77
Inhibition of c-Jun N-terminal kinase activity enhances vestibular schwannoma cell sensitivity to gamma irradiation. Neurosurgery (2013) 0.75
The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors. Oncogene (2015) 0.75
Partial Blindness to Submicron Topography in NF1 Haploinsufficient Cultured Fibroblasts Indicates a New Function of Neurofibromin in Regulation of Mechanosensoric. Mol Syndromol (2012) 0.75
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration. Oncologist (2017) 0.75
BAY 61-3606, CDKi, and sodium butyrate treatments alter gene expression in human vestibular schwannomas and cause cell death in vitro. Ecancermedicalscience (2012) 0.75
Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. EBioMedicine (2017) 0.75
Rac1-Mediated DNA Damage and Inflammation Promote Nf2 Tumorigenesis but Also Limit Cell-Cycle Progression. Dev Cell (2016) 0.75
p53 performs an essential role in mediating the oncogenic stimulus triggered by loss of expression of neurofibromatosis type 2 during in vitro tumor progression. Oncol Lett (2017) 0.75
Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurol (2015) 2.51
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell (2010) 2.38
X-linked bulbospinal neuronopathy: Kennedy disease. Arch Neurol (2002) 2.21
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J (2004) 1.85
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A (2013) 1.72
Cannabinoid receptor and N-acyl phosphatidylethanolamine phospholipase D--evidence for altered expression in multiple sclerosis. Brain Pathol (2011) 1.52
Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet (2003) 1.47
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A (2011) 1.24
ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol (2010) 1.04
Laryngospasm: an underdiagnosed symptom of X-linked spinobulbar muscular atrophy. Neurology (2005) 1.01
Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy. Nat Neurosci (2013) 1.01
The tumor suppressor merlin controls growth in its open state, and phosphorylation converts it to a less-active more-closed state. Dev Cell (2012) 0.97
Merlin, a multi-suppressor from cell membrane to the nucleus. FEBS Lett (2012) 0.92
Emerging therapeutic targets in schwannomas and other merlin-deficient tumors. Nat Rev Neurol (2011) 0.92
Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression. Sci Signal (2011) 0.89
Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ. Histopathology (2009) 0.88
Reduced apoptosis rates in human schwannomas. Brain Pathol (2005) 0.88
Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma. Brain Pathol (2008) 0.87
Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228. Cancer Biol Ther (2005) 0.87
Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244. Neurobiol Dis (2009) 0.86
Pathological adhesion of primary human schwannoma cells is dependent on altered expression of integrins. Brain Pathol (2003) 0.84
Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting. Acta Neuropathol (2011) 0.83
Achieving consensus for clinical trials: the REiNS International Collaboration. Neurology (2013) 0.82
MR-pathologic comparison of the upper spinal cord in different motor neuron diseases. Eur Neurol (2005) 0.81
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am J Med Genet A (2014) 0.81
Acquired neuromyotonia following upper respiratory tract infection: a case report. Cases J (2009) 0.81
Rearrangements of the intermediate filament GFAP in primary human schwannoma cells. Neurobiol Dis (2005) 0.80
Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. J Neurol (2014) 0.79
Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells. Brain (2013) 0.79
The role of insulin-like growth factors signaling in merlin-deficient human schwannomas. Glia (2012) 0.79
Sensitive detection of deletions of one or more exons in the neurofibromatosis type 2 (NF2) gene by multiplexed gene dosage polymerase chain reaction. J Mol Diagn (2005) 0.79
The epidemiology of motor neurone disease in two counties in the southwest of England. J Neurol (2010) 0.79
Unilateral cerebral hemisphere oedema as a peri-ictal phenomenon. J Neurol (2010) 0.78
Medulloblastoma in a patient with the PTPN11 p.Thr468Met mutation. Am J Med Genet A (2013) 0.77
Cadmium toxicity related to cysteine metabolism and glutathione levels in frog Rana ridibunda tissues. Comp Biochem Physiol C Toxicol Pharmacol (2005) 0.76
Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues. Am J Med Genet A (2014) 0.76
Complicated hereditary spastic paraplegia with thin corpus callosum: variation of phenotypic expression over time. J Neurol (2004) 0.75
Genetic analysis of a UNAIDS HIV type 1 from Brazil revealed an unexpected recombination pattern. AIDS Res Hum Retroviruses (2010) 0.75
Management of sialorrhoea in motor neuron disease: a survey of current UK practice. Amyotroph Lateral Scler Frontotemporal Degener (2013) 0.75